Select Clinical Trial
GOG 225: Can Diet and Physical Activity Modulate Ovarian and Primary Peritoneal Cancer Progression-Free Survival
- Women, ages 18 years or older, with confirmed ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call the Research Coordinator or visit the study weblink our Clinical Trials office at (910) 715-2200.
NRG-GY005/ Ovarian/ Fallopian Tube/ Peritoneal
- Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
- Patient population 18 Years and older with confirmed ovarian cancer, peritoneal cancer or fallopian tube cancerthat has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).